Cysteinylation of MHC Class II Ligands: Peptide Endocytosis and Reduction Within APC Influences T Cell Recognition1

Peptides bind cell surface MHC class II proteins to yield complexes capable of activating CD4+ T cells. By contrast, protein Ags require internalization and processing by APC before functional presentation. Here, T cell recognition of a short peptide in the context of class II proteins occurred only after delivery of this ligand to mature endosomal/lysosomal compartments within APC. Functional and biochemical studies revealed that a central cysteine within the peptide was cysteinylated, perturbing T cell recognition of this epitope. Internalization and processing of the modified epitope by APC, was required to restore T cell recognition. Peptide cysteinylation and reduction could occur rapidly and reversibly before MHC binding. Cysteinylation did not disrupt peptide binding to class II molecules, rather the modified peptide displayed an enhanced affinity for MHC at neutral pH. However, once the peptide was bound to class II proteins, oxidation or reduction of cysteine residues was severely limited. Cysteinylation has been shown to radically influence T cell responses to MHC class I ligands. The ability of professional APC to reductively cleave this peptide modification presumably evolved to circumvent a similar problem in MHC class II ligand recognition.

[1]  Y. Ishii,et al.  Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Blum,et al.  Endocytic Recycling is Required for the Presentation of an Exogenous Peptide via MHC Class II Molecules , 2000, Traffic.

[3]  E. Sercarz,et al.  Processing and Reactivity of T Cell Epitopes Containing Two Cysteine Residues from Hen Egg-White Lysozyme (HEL74–90)1 , 2000, The Journal of Immunology.

[4]  P. Cresswell,et al.  Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Strominger,et al.  Extracellular antigen processing and presentation by immature dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Zaller,et al.  Role of APC in the selection of immunodominant T cell epitopes. , 1999, Journal of immunology.

[7]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[8]  C. Walsh,et al.  Tandem heterocyclization activity of the multidomain 230 kDa HMWP2 subunit of Yersinia pestis yersiniabactin synthetase: interaction of the 1-1382 and 1383-2035 fragments. , 1999, Biochemistry.

[9]  A. Rosen,et al.  Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.

[10]  S. Brennan,et al.  Albumin banks peninsula: a new termination variant characterised by electrospray mass spectrometry. , 1999, Biochimica et biophysica acta.

[11]  R. Steinman,et al.  Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. , 1999, Blood.

[12]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[13]  R. Steinman,et al.  Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. , 1999, Human immunology.

[14]  J. Yewdell,et al.  Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.

[15]  K. Sakaguchi,et al.  Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. , 1998, Journal of immunology.

[16]  K. Takahashi,et al.  Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. , 1998, Molecular immunology.

[17]  C. Janeway,et al.  Exogenously Provided Peptides of a Self-antigen Can Be Processed into Forms that Are Recognized by Self–T Cells , 1998, The Journal of experimental medicine.

[18]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[19]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[20]  M. Bevan,et al.  Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. , 1998, Immunity.

[21]  F. Modugno,et al.  MHC‐Peptide Binding: Dimers of Cysteine‐Containing Nonapeptides Bind with High Affinity to HLA‐A2.1 Class I Molecules , 1997, Journal of immunotherapy.

[22]  M. Bevan,et al.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. , 1997, Blood.

[23]  C. Watts,et al.  Characterization of transport of newly assembled, T cell-stimulatory MHC class II-peptide complexes from MHC class II compartments to the cell surface. , 1997, Journal of immunology.

[24]  D. Pious,et al.  Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. , 1997, Journal of Immunology.

[25]  M. Bevan,et al.  Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.

[26]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[27]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[28]  B. Evavold,et al.  Enhanced Dissociation of HLA-DR-Bound Peptides in the Presence of HLA-DM , 1996, Science.

[29]  Y. Chien,et al.  Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface , 1996, The Journal of experimental medicine.

[30]  D. Fremont,et al.  Structures of an MHC Class II Molecule with Covalently Bound Single Peptides , 1996, Science.

[31]  D. Weber,et al.  DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. , 1995, Immunity.

[32]  P. Cresswell,et al.  HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading , 1995, Cell.

[33]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[34]  Eric O Long,et al.  Antigen presentation mediated by recycling of surface HLA-DR molecules , 1995, Nature.

[35]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[36]  P. Cresswell,et al.  Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles , 1995, The Journal of experimental medicine.

[37]  K. McCoy,et al.  Characterization of fibroblasts with a unique defect in processing antigens with disulfide bonds. , 1995, Journal of immunology.

[38]  A. Rudensky,et al.  Intracellular assembly and transport of endogenous peptide-MHC class II complexes. , 1994, Immunity.

[39]  G. Nepom,et al.  Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome , 1994, The Journal of experimental medicine.

[40]  H. Ploegh,et al.  Isolation and characterization of the intracellular MHC class II compartment , 1994, Nature.

[41]  A. Wandinger-Ness,et al.  Separation of subcellular compartments containing distinct functional forms of MHC class II , 1994, The Journal of cell biology.

[42]  J. Rothbard,et al.  Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. , 1994, Journal of immunology.

[43]  P. Jensen,et al.  Membrane interactions influence the peptide binding behavior of DR1 , 1994, The Journal of experimental medicine.

[44]  H. Geuze,et al.  Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. , 1993, Journal of immunology.

[45]  J. Gariépy,et al.  Characterization of the insulin A-chain major immunogenic determinant presented by MHC class II I-Ad molecules. , 1993, Journal of immunology.

[46]  P. Højrup,et al.  Amino acid exchange and covalent modification by cysteine and glutathione explain isoforms of fatty acid-binding protein occurring in bovine liver. , 1993, The Journal of biological chemistry.

[47]  K. Magnusson,et al.  Microtubules are involved in transport of macromolecules by vesicles in cultured bovine aortic endothelial cells , 1993, Journal of cellular physiology.

[48]  P. Jensen,et al.  Acidification and disulfide reduction can be sufficient to allow intact proteins to bind class II MHC. , 1993, Journal of immunology.

[49]  L. Otvos,et al.  Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells , 1992, Journal of virology.

[50]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[51]  E. Unanue,et al.  Reduction of disulfide bonds within lysosomes is a key step in antigen processing. , 1991, Journal of immunology.

[52]  P. Jensen Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant , 1991, The Journal of experimental medicine.

[53]  P. Jensen,et al.  Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH , 1991, The Journal of experimental medicine.

[54]  A. Rudensky,et al.  Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.

[55]  R. Germain,et al.  MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding , 1991, Nature.

[56]  J. Berzofsky,et al.  Recognition of peptides that are immunopathogenic but cryptic. Mechanisms that allow lymphocytes sensitized against cryptic peptides to initiate pathogenic autoimmune processes. , 1991, Journal of immunology.

[57]  J. Hansen,et al.  Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Emil R. Unanue,et al.  Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation , 1990, Nature.

[59]  G. Ferrara,et al.  Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells , 1989, Nature.

[60]  M. Bevan,et al.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization , 1989, The Journal of experimental medicine.

[61]  P. Allen,et al.  Binding to Ia protects an immunogenic peptide from proteolytic degradation. , 1989, Journal of immunology.

[62]  C. Granier,et al.  Processing by accessory cells for presentation to murine T cells of apamin, a disulfide-bonded 18 amino acid peptide. , 1988, Journal of immunology.

[63]  R. Germain,et al.  Processing of a minimal antigenic peptide alters its interaction with MHC molecules , 1988, Nature.

[64]  B. Singh,et al.  Processing and presentation of insulin. I. Analysis of immunogenic peptides and processing requirements for insulin A loop-specific T cells. , 1987, Journal of immunology.

[65]  H. Geuze,et al.  Sorting of endocytosed transferrin and asialoglycoprotein occurs immediately after internalization in HepG2 cells , 1987, The Journal of cell biology.

[66]  B. Storrie,et al.  Effects of temperature, pH elevators, and energy production inhibitors on horseradish peroxidase transport through endocytic vesicles , 1987, Journal of cellular physiology.

[67]  A Sette,et al.  The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.

[68]  A. Hubbard,et al.  Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway , 1986, The Journal of cell biology.

[69]  A. Bolognesi,et al.  Recycling of the asialoglycoprotein receptor and the effect of lysosomotropic amines in hepatoma cells , 1984, The Journal of cell biology.

[70]  H. Grey,et al.  Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing , 1983, The Journal of experimental medicine.

[71]  P. Weigel,et al.  Endocytosis and degradation mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. , 1982, The Journal of biological chemistry.

[72]  P. Marrack,et al.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition , 1981, The Journal of experimental medicine.

[73]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[74]  R. Germain,et al.  Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway and appearance of peptide-loaded class II in multiple compartments. , 1995, Immunity.

[75]  I Mellman,et al.  Acidification of the endocytic and exocytic pathways. , 1986, Annual review of biochemistry.